INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-69895-01
	Application Number	10/517,154
	Filing Date	December 6, 2004
	First Named Inventor	Morishita
	Art Unit	~~1642~~ *1632*
	Examiner Name	~~Not yet assigned~~ *PAUL POWELL*

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
PP		Europe	1132098 A1	09/12/2001	MedGene Bioscience, Inc.
PP		Europe	722737 A1	07/24/1996	Sumitomo Pharmaceuticals Co.
PP		Europe	1170363 A1	01/09/2002	Kaneda, Yasufumi
PP		WIPO	WO 01/26694 A1 (w/English Translation)	04/19/2001	MedGene Bioscience, Inc.
PP		WIPO	WO 01/32220 A1 (w/English Translation)	05/10/2001	MedGene Bioscience, Inc.
PP		WIPO	WO 02/089854 A1 (w/English Translation)	11/14/2002	Anges Mg, Inc.

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
PP		Hayashi et al., "Gene Therapy for Preventing Neuronal Death Using Hepatocyte Growth Factor: *In Vivo* Gene Transfer of HGF to Subarachnoid Space Prevents Delayed Neuronal Death in Gerbil Hippocampal CA1 Neurons," *Gene Ther.* 8:1167-1173 (2001).
PP		~~Ishida et al., "Nokosoku (Nokyoketsu) ni Taisuru Idenshi Chiryo, Noshinkei," 2002 March, Vol. 54, No. 3, pages 213 to 219.~~

EXAMINER SIGNATURE:	*[signature]*	DATE CONSIDERED:	10/7/2005

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.